GLAVINE PAUL enters HELUS PHARMA INC. with 4.21M shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Indirect Derivatives
Filed: 9/9/2026ACC: 0000912282-26-001245
Officer· Chief Growth Officer
Since Aug 2026
4.21M
Baseline shares
95% direct
3.98M
Direct ownership
1 position
105.26K
Derivative underlying
1 instrument
2
Security positions
230.94K indirect
Non-Derivative Holdings2
Common Shares
DirectShares owned3.98M
Common Shares
IndirectShares owned230.94K
Total
3.98M direct·230.94K indirect4.21M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Shares | 3.98M | Direct |
| Common Shares | 230.94K | Indirect |
| Total | 4.21M | 3.98M direct·230.94K indirect |
Derivative Holdings1
Warrants
IndirectUnderlying security
Common Shares
Underlying shares
105.26K
Shares owned
N/A
Exercise price
Expiration
—
Exercise window
—
Total
Underlying
105.26K
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Warrants Indirect | Common Shares | — | — | 105.26K | N/A | |
| Total | 105.26K | 0.00 | ||||